Importantly, we also observed the decrease of FGFR2 phosphorylation in CB-treated GIST T-1R cells, thus suggesting the novel molecular mechanism responsible for CB’s effectiveness in IM-resistant GISTs exhibiting this specific type of RTK switch (loss of KIT/gain of FGFR). The gene discussed is FGFR2; the disease is gastrointestinal stromal tumor.